Literature DB >> 20138090

Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB.

Maria M Canal1, Fiona L Wilkinson, Jonathan D Cooper, J Ed Wraith, Rob Wynn, Brian W Bigger.   

Abstract

Mucopolysaccharidosis IIIB (MPSIIIB) is a lysosomal storage disease characterised by progressive central nervous system degeneration in patients, with death usually in the late teens. Serious behavioural problems have been reported in children at the early stages of the disease, such as hyperactivity and severe sleep disturbances, which suggest alterations in circadian rhythms. We investigated the circadian rhythm of locomotor activity of young and old MPSIIIB mice, under a 24-h light-dark (LD) cycle and under constant darkness (DD), and also examined neuropeptide expression in the suprachiasmatic nucleus (SCN), site of the principal biological pacemaker. We show that MPSIIIB mice have higher activity levels during the light (resting) phase of the LD cycle, together with weaker circadian rhythms, and a longer active phase due to a late peak of activity, in both LD and DD. In addition, young MPSIIIB mice showed shorter phase delays in response to a light pulse in DD. Increased lysosomal storage, neuroinflammation and changes in the expression of Arginine Vasopressin and Vasointestinal Polypeptide, two circadian neuropeptides, were observed in the SCN, which may be in part responsible for the changes in circadian behaviour observed in MPSIIIB mice. These findings suggest an alteration of the circadian system in MPSIIIB mice, and may inform better clinical management of circadian, sleep and behavioural disturbances in patients with MPSIII. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138090     DOI: 10.1016/j.bbr.2010.01.045

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  19 in total

1.  Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.

Authors:  Alexander Langford-Smith; Fiona L Wilkinson; Kia J Langford-Smith; Rebecca J Holley; Ana Sergijenko; Steven J Howe; William R Bennett; Simon A Jones; Je Wraith; Catherine Lr Merry; Robert F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

2.  Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation.

Authors:  Fiona L Wilkinson; Ana Sergijenko; Kia J Langford-Smith; Marcela Malinowska; Rob F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

3.  Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.

Authors:  Marcelina Malinowska; Fiona L Wilkinson; Kia J Langford-Smith; Alex Langford-Smith; Jillian R Brown; Brett E Crawford; Marie T Vanier; Grzegorz Grynkiewicz; Rob F Wynn; J Ed Wraith; Grzegorz Wegrzyn; Brian W Bigger
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

4.  Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test.

Authors:  Alex Langford-Smith; Kia J Langford-Smith; Simon A Jones; Robert F Wynn; J E Wraith; Fiona L Wilkinson; Brian W Bigger
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

5.  Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases.

Authors:  Kia Jane Langford-Smith; Jean Mercer; June Petty; Karen Tylee; Heather Church; Jane Roberts; Gill Moss; Simon Jones; Rob Wynn; J Ed Wraith; Brian W Bigger
Journal:  J Inherit Metab Dis       Date:  2010-12-18       Impact factor: 4.982

6.  Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B.

Authors:  Kazuhiro Ohmi; Hui-Zhi Zhao; Elizabeth F Neufeld
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

7.  Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.

Authors:  Fiona L Wilkinson; Rebecca J Holley; Kia J Langford-Smith; Soumya Badrinath; Aiyin Liao; Alex Langford-Smith; Jonathan D Cooper; Simon A Jones; J Ed Wraith; Rob F Wynn; Catherine L R Merry; Brian W Bigger
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

8.  Assessment of sleep in children with mucopolysaccharidosis type III.

Authors:  Louise Victoria Mahon; Michelle Lomax; Sheena Grant; Elaine Cross; Dougal Julian Hare; James Ed Wraith; Simon Jones; Brian Bigger; Kia Langford-Smith; Maria Canal
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

9.  Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease.

Authors:  Ana Sergijenko; Alexander Langford-Smith; Ai Y Liao; Claire E Pickford; John McDermott; Gabriel Nowinski; Kia J Langford-Smith; Catherine L R Merry; Simon A Jones; J Edmond Wraith; Robert F Wynn; Fiona L Wilkinson; Brian W Bigger
Journal:  Mol Ther       Date:  2013-06-07       Impact factor: 11.454

10.  Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome).

Authors:  Rachel A Mumford; Louise V Mahon; Simon Jones; Brian Bigger; Maria Canal; Dougal Julian Hare
Journal:  J Neurodev Disord       Date:  2015-09-01       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.